The influence of long-time eprosartan therapy on left ventricle geometriy and function in patients with arterial hypertension and diastolic dysfunction
Abstract
Purpose: To study the effects of 48 weeks eprosartan therapy on left ventricle (LV) geometry and function condition.
Materials and methods: investigate 34 patients with arterial hypertension 1-2 stage with LV diastolic dysfunction. All patients randomized in 2 groups. Patients in either group received eprosartan in dose 600 mg p/day monotherapy, in other group – 20 mg 2 p/day nifedipine.
Results: At the end of therapy in group with eprosartan occurred reliable normalization geometry end effective tendencies of normalization of diastolic function, at the same time change in other group were non reliable.
Summury: Thus eprosartan is high effective remedy for prevention of HF in patient with arterial hypertension.
About the Authors
E. V. Osipov
Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine №2
29 Nakhichevansky st., Rostov-on-Don, 344022I. I. Anufriev
Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine №2
29 Nakhichevansky st., Rostov-on-Don, 344022S. A. Zatonskii
Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine №2
29 Nakhichevansky st., Rostov-on-Don, 344022M. I. Nazheva
Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine №2
29 Nakhichevansky st., Rostov-on-Don, 344022References
1. Терещенко С.Н., Демидова И.В., Александрия Л.Г., Агеев Ф.Т. Диастолическая дисфункция левого желудочка и ее роль в развитии хронической сердечной недостаточности. // Сердечная недостаточность. - 2000. – Т.1, №2. – С.61-65
2. Pitt B, Poole–Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losar tan Hear t Failure Survival Study ELITE II //Lancet. – 2000. - №355 (9215). – P.1582 –1587.
3. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) //Circulation. – 2002. - №106. – P.2454-58.
4. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial //Lancet. – 2003. - №362. – P.754-55.
5. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial //Lancet. – 2003. - №362. – P.767-71.
6. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme //Lancet. – 2003. - №362. – P.759-66.
7. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction //N Engl J Med. – 2008. - №359. – P.2456—2467.
8. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation //Circulation. – 1997. - №96. – P.4065–82.
9. Kahan T. the importance of left ventricular hypertrophy in human hypertension //J Hypertens Suppl. – 1998. - №16. – P.23-29
Review
For citations:
Osipov E.V., Anufriev I.I., Zatonskii S.A., Nazheva M.I. The influence of long-time eprosartan therapy on left ventricle geometriy and function in patients with arterial hypertension and diastolic dysfunction. Medical Herald of the South of Russia. 2010;(1):44-47. (In Russ.)
Views:
279
Email this article 